COMPANY

Ophirex, Inc.

HQ: Corte Madera, CA source · ophirex.com ↗ · West Coast

Also known as Ophirex · 6 sources

Location: Corte Madera, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Snake Envenoming Snakebites Envenoming Snake Envenomation Snakebite Coronavirus Disease 2019 Varespladib

Timeline

Jul 21, 2025 Grant Government grant — NIH R01: $1.11M (annual award, as published), announced Jul 21, 2025. Agency: NIH/FDA. Source: government award database. source ↗
May 30, 2023 Trial start Phase 2: Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) source ↗
Aug 15, 2021 Trial start Phase 2: Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite source ↗
Jun 30, 2021 Trial start Phase 2: Study of Varespladib in Patients Hospitalized With Severe COVID-19 source ↗

Last 2 years.

Jul 21, 2025 Government grant — NIH R01: $1.11M (annual award, as published), announced Jul 21, 2025. Agency: NIH/FDA. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04996264	Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite	Phase 2	Completed	Aug 15, 2021	Jun 7, 2023 (actual)
NCT05717062	Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)	Phase 2	Completed	May 30, 2023	Nov 28, 2024 (actual)
NCT04969991	Study of Varespladib in Patients Hospitalized With Severe COVID-19	Phase 2	Terminated	Jun 30, 2021	Feb 11, 2022 (actual)

Annual award amounts. Total $1.8M.

Sep 15, 2024 NIH award 5R01FD007839-02 FY2024: $886,309 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PLATTS-MILLS, TIM; recipient as written: OPHIREX, INC., CORTE MADERA, CA. Development of Intravenous Varespladib, source ↗
Sep 20, 2023 NIH award 1R01FD007839-01A1 FY2023: $894,459 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PLATTS-MILLS, TIM; recipient as written: OPHIREX, INC., CORTE MADERA, CA. Development of Intravenous Varespladib source ↗